Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies
BackgroundAntibody-drug conjugates (ADCs) play an important role in the targeted therapy of gynecological malignancies. The purpose of this study was to investigate the expression of targets in gynecologic malignancies in order to predict the selection of targets for the development of antibody-drug...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1525733/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849716466949029888 |
|---|---|
| author | Yuying Jiang Yuance Xu Junqi He Lei Sui Tian Li Nannan Xia Qin Yao |
| author_facet | Yuying Jiang Yuance Xu Junqi He Lei Sui Tian Li Nannan Xia Qin Yao |
| author_sort | Yuying Jiang |
| collection | DOAJ |
| description | BackgroundAntibody-drug conjugates (ADCs) play an important role in the targeted therapy of gynecological malignancies. The purpose of this study was to investigate the expression of targets in gynecologic malignancies in order to predict the selection of targets for the development of antibody-drug conjugates.MethodsIn this article, we identified existing ADCs and their targets through clinical trial databases and public genomic datasets, performed differential analysis of tumor antigen targets (TATs) expression between tumor and normal tissues, and evaluated the necessity of the targets for tumor cell lines.ResultsIn gynecologic malignancies, we have identified several highly expressed TATs, some of which have been targeted by FDA-approved ADCs, such as TROP2 and Nectin-4, although these drugs have not been approved for the treatment of gynecologic cancers. At the same time, we also observed that some targets of ADCs that have not yet been approved by the FDA also show high expression levels in gynecologic malignancies tissues, such as MSLN, ERBB3, NaPi2b, etc. Furthermore, we identified TATs with high expression levels in various pathological subtypes of ovarian, endometrial, and cervical cancer. Notably, some TATs are crucial to the survival of tumor cells, such as CD71, TOP1, and TDGF1, which are essential for the survival of ovarian, endometrial, cervical, and other tumor cells.ConclusionWe have innovatively predicted the potential targets of ADCs in treating gynecological malignancies and provided a new perspective on applying some FDA-approved ADCs in indications for gynecological cancers. |
| format | Article |
| id | doaj-art-2ca9450ddf634d67acac94381a4d881a |
| institution | DOAJ |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-2ca9450ddf634d67acac94381a4d881a2025-08-20T03:12:58ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-02-011610.3389/fphar.2025.15257331525733Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignanciesYuying Jiang0Yuance Xu1Junqi He2Lei Sui3Tian Li4Nannan Xia5Qin Yao6Department of Obstetrics and Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, ChinaDepartment of Obstetrics and Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, ChinaDepartment of Obstetrics and Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, ChinaDepartment of Obstetrics and Gynecology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, ChinaDepartment of Obstetrics and Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, ChinaDepartment of Obstetrics and Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, ChinaDepartment of Obstetrics and Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, ChinaBackgroundAntibody-drug conjugates (ADCs) play an important role in the targeted therapy of gynecological malignancies. The purpose of this study was to investigate the expression of targets in gynecologic malignancies in order to predict the selection of targets for the development of antibody-drug conjugates.MethodsIn this article, we identified existing ADCs and their targets through clinical trial databases and public genomic datasets, performed differential analysis of tumor antigen targets (TATs) expression between tumor and normal tissues, and evaluated the necessity of the targets for tumor cell lines.ResultsIn gynecologic malignancies, we have identified several highly expressed TATs, some of which have been targeted by FDA-approved ADCs, such as TROP2 and Nectin-4, although these drugs have not been approved for the treatment of gynecologic cancers. At the same time, we also observed that some targets of ADCs that have not yet been approved by the FDA also show high expression levels in gynecologic malignancies tissues, such as MSLN, ERBB3, NaPi2b, etc. Furthermore, we identified TATs with high expression levels in various pathological subtypes of ovarian, endometrial, and cervical cancer. Notably, some TATs are crucial to the survival of tumor cells, such as CD71, TOP1, and TDGF1, which are essential for the survival of ovarian, endometrial, cervical, and other tumor cells.ConclusionWe have innovatively predicted the potential targets of ADCs in treating gynecological malignancies and provided a new perspective on applying some FDA-approved ADCs in indications for gynecological cancers.https://www.frontiersin.org/articles/10.3389/fphar.2025.1525733/fullantibody-drug conjugates (ADCs)target predictiontargeted therapygynecological malignanciesnew therapies |
| spellingShingle | Yuying Jiang Yuance Xu Junqi He Lei Sui Tian Li Nannan Xia Qin Yao Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies Frontiers in Pharmacology antibody-drug conjugates (ADCs) target prediction targeted therapy gynecological malignancies new therapies |
| title | Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies |
| title_full | Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies |
| title_fullStr | Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies |
| title_full_unstemmed | Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies |
| title_short | Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies |
| title_sort | uncovering potential targets for antibody drug conjugates in the treatment of gynecologic malignancies |
| topic | antibody-drug conjugates (ADCs) target prediction targeted therapy gynecological malignancies new therapies |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1525733/full |
| work_keys_str_mv | AT yuyingjiang uncoveringpotentialtargetsforantibodydrugconjugatesinthetreatmentofgynecologicmalignancies AT yuancexu uncoveringpotentialtargetsforantibodydrugconjugatesinthetreatmentofgynecologicmalignancies AT junqihe uncoveringpotentialtargetsforantibodydrugconjugatesinthetreatmentofgynecologicmalignancies AT leisui uncoveringpotentialtargetsforantibodydrugconjugatesinthetreatmentofgynecologicmalignancies AT tianli uncoveringpotentialtargetsforantibodydrugconjugatesinthetreatmentofgynecologicmalignancies AT nannanxia uncoveringpotentialtargetsforantibodydrugconjugatesinthetreatmentofgynecologicmalignancies AT qinyao uncoveringpotentialtargetsforantibodydrugconjugatesinthetreatmentofgynecologicmalignancies |